In this issue:
Bimekizumab for moderate-to-severe plaque psoriasis
Nail psoriasis targeted therapies
Apremilast long-term safety in psoriasis, psoriatic arthritis, and Behçet’s syndrome
Early guselkumab use in psoriasis
Guselkumab for difficult-to-treat psoriasis in Asian patients
Early discontinuation of apremilast
Methotrexate vs methotrexate + apremilast in chronic plaque psoriasis
Secukinumab in paediatric patients with plaque psoriasis
Please login below to download this issue (PDF)